![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GFOD1 |
Gene summary for GFOD1 |
![]() |
Gene information | Species | Human | Gene symbol | GFOD1 | Gene ID | 54438 |
Gene name | glucose-fructose oxidoreductase domain containing 1 | |
Gene Alias | ADG-90 | |
Cytomap | 6p24.1-p23 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NXC2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54438 | GFOD1 | P107T-E | Human | Esophagus | ESCC | 1.58e-14 | 3.96e-01 | 0.171 |
54438 | GFOD1 | P127T-E | Human | Esophagus | ESCC | 2.96e-11 | 1.42e-01 | 0.0826 |
54438 | GFOD1 | P128T-E | Human | Esophagus | ESCC | 6.29e-08 | 2.94e-01 | 0.1241 |
54438 | GFOD1 | P130T-E | Human | Esophagus | ESCC | 3.82e-40 | 7.62e-01 | 0.1676 |
54438 | GFOD1 | C04 | Human | Oral cavity | OSCC | 4.04e-10 | 5.56e-01 | 0.2633 |
54438 | GFOD1 | C21 | Human | Oral cavity | OSCC | 1.31e-10 | 4.47e-01 | 0.2678 |
54438 | GFOD1 | C30 | Human | Oral cavity | OSCC | 2.38e-31 | 1.15e+00 | 0.3055 |
54438 | GFOD1 | C43 | Human | Oral cavity | OSCC | 4.47e-13 | 3.02e-01 | 0.1704 |
54438 | GFOD1 | C46 | Human | Oral cavity | OSCC | 4.67e-10 | 2.67e-01 | 0.1673 |
54438 | GFOD1 | C51 | Human | Oral cavity | OSCC | 5.62e-13 | 6.54e-01 | 0.2674 |
54438 | GFOD1 | C57 | Human | Oral cavity | OSCC | 4.50e-05 | 2.77e-01 | 0.1679 |
54438 | GFOD1 | C06 | Human | Oral cavity | OSCC | 1.15e-04 | 6.79e-01 | 0.2699 |
54438 | GFOD1 | C08 | Human | Oral cavity | OSCC | 1.42e-02 | 1.31e-01 | 0.1919 |
54438 | GFOD1 | LN22 | Human | Oral cavity | OSCC | 2.64e-04 | 6.29e-01 | 0.1733 |
54438 | GFOD1 | LN46 | Human | Oral cavity | OSCC | 6.12e-03 | 2.37e-01 | 0.1666 |
54438 | GFOD1 | SYSMH2 | Human | Oral cavity | OSCC | 1.17e-05 | 2.21e-01 | 0.2326 |
54438 | GFOD1 | SYSMH3 | Human | Oral cavity | OSCC | 7.09e-15 | 4.36e-01 | 0.2442 |
54438 | GFOD1 | SYSMH5 | Human | Oral cavity | OSCC | 2.36e-06 | 1.81e-01 | 0.0647 |
54438 | GFOD1 | HTA12-23-1 | Human | Pancreas | PDAC | 1.28e-03 | 5.30e-01 | 0.3405 |
54438 | GFOD1 | HTA12-25-1 | Human | Pancreas | PDAC | 4.48e-07 | 6.39e-01 | 0.313 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
GO:003406315 | Esophagus | ESCC | stress granule assembly | 23/8552 | 26/18723 | 6.82e-06 | 6.90e-05 | 23 |
GO:00181263 | Esophagus | ESCC | protein hydroxylation | 23/8552 | 27/18723 | 2.60e-05 | 2.19e-04 | 23 |
GO:00432446 | Esophagus | ESCC | regulation of protein-containing complex disassembly | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
GO:00195114 | Esophagus | ESCC | peptidyl-proline hydroxylation | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
GO:00436245 | Esophagus | ESCC | cellular protein complex disassembly | 78/8552 | 136/18723 | 4.00e-03 | 1.62e-02 | 78 |
GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
GO:00340632 | Liver | HCC | stress granule assembly | 24/7958 | 26/18723 | 1.35e-07 | 2.57e-06 | 24 |
GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
GO:00432444 | Liver | HCC | regulation of protein-containing complex disassembly | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
GO:0018126 | Liver | HCC | protein hydroxylation | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
GO:00436242 | Liver | HCC | cellular protein complex disassembly | 71/7958 | 136/18723 | 1.39e-02 | 4.95e-02 | 71 |
GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
GO:003298410 | Oral cavity | OSCC | protein-containing complex disassembly | 136/7305 | 224/18723 | 3.42e-11 | 1.13e-09 | 136 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GFOD1 | SNV | Missense_Mutation | c.904N>C | p.Tyr302His | p.Y302H | Q9NXC2 | protein_coding | tolerated(0.21) | benign(0.067) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GFOD1 | SNV | Missense_Mutation | c.889N>A | p.Asp297Asn | p.D297N | Q9NXC2 | protein_coding | tolerated(0.13) | benign(0.031) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR | |
GFOD1 | SNV | Missense_Mutation | novel | c.121N>A | p.Glu41Lys | p.E41K | Q9NXC2 | protein_coding | tolerated(0.29) | benign(0.145) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GFOD1 | SNV | Missense_Mutation | novel | c.14T>C | p.Val5Ala | p.V5A | Q9NXC2 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GFOD1 | SNV | Missense_Mutation | novel | c.112N>A | p.Glu38Lys | p.E38K | Q9NXC2 | protein_coding | tolerated(0.16) | benign(0.395) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
GFOD1 | SNV | Missense_Mutation | c.817N>G | p.Pro273Ala | p.P273A | Q9NXC2 | protein_coding | tolerated(0.76) | benign(0) | TCGA-AA-3680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | PD | |
GFOD1 | SNV | Missense_Mutation | c.814N>C | p.Ala272Pro | p.A272P | Q9NXC2 | protein_coding | tolerated(0.06) | benign(0.259) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GFOD1 | SNV | Missense_Mutation | c.34N>T | p.Leu12Phe | p.L12F | Q9NXC2 | protein_coding | tolerated(0.05) | possibly_damaging(0.588) | TCGA-QG-A5YX-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR | |
GFOD1 | SNV | Missense_Mutation | novel | c.1120N>A | p.Ala374Thr | p.A374T | Q9NXC2 | protein_coding | tolerated(0.28) | benign(0.123) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GFOD1 | SNV | Missense_Mutation | c.376N>T | p.Pro126Ser | p.P126S | Q9NXC2 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |